Medtronic Faces $382M Antitrust Judgment Over Surgical Stapler Market Exclusion
Medtronic has been ordered to pay $382 million following a jury verdict in an antitrust suit alleging it used exclusionary bundling practices in surgical stapler devices. The ruling could prompt the company to increase legal provisions and face tougher oversight in contracts for its core surgical portfolio.
1. Verdict Details
A US jury concluded that Medtronic unlawfully tied its surgical stapler products to accessory supplies between 2013 and 2020, awarding $382 million in damages to a competing device manufacturer. The verdict deemed these exclusionary practices as anticompetitive, leading to the substantial judgment.
2. Financial Impact
Medtronic is expected to record a one-time charge in its current quarter to cover the $382 million payout, which may pressure its operating margins and delay share repurchases or dividend increases. The company’s fiscal 2026 guidance could be revisited pending appeal outcomes and further legal reserves.
3. Legal Response and Outlook
The company has signaled its intention to appeal the ruling, arguing the decision mischaracterizes its sales contracts. This case heightens regulatory scrutiny over sales practices in the medical device industry, potentially prompting Medtronic to revise contract terms or face additional legal challenges.